A Real-World Evidence Study for the Incidence of Retinal Vasculitis (RV) Among Adult Patients Receiving Aflibercept 2 mg in the United States (US)
← catalyst calendarSponsored by Regeneron Pharmaceuticals (industry) · REGN — their whole pipeline →.
Phase
—
Status
Completed
Study type
Observational
Enrollment
550,000actual
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-07-01 | actual | When the study began enrolling |
| Primary completion | 2025-08-15 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-09-01 | actual | The whole study's end, after follow-up |
| First posted | 2025-01-10 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-10-29 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Retinal Vasculitis
Intervention
- Drug: aflibercept 2 mg — also filed as Eylea®
Primary outcomes
what the primary-completion date above is the date OFIncidence of RV events
measured During the 60-Day at-risk period following aflibercept 2 mg IVT, up to approximately 6.5 years
Incidence of occlusive RV events confirmed through clinical chart abstraction
measured During the 60-Day at-risk period following aflibercept 2 mg IVT, up to approximately 6.5 years
Incidence of non-occlusive RV events confirmed through clinical chart abstraction
measured During the 60-Day at-risk period following aflibercept 2 mg IVT, up to approximately 6.5 years
Incidence of unconfirmed RV events
measured During the 60-Day at-risk period following aflibercept 2 mg IVT, up to approximately 6.5 years
Permalink · REGN's whole pipeline · Catalyst calendar · Every registered study · What changed